550 | PHASE II TRIAL OF ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE CWCLL‐001 TRIAL

Documenti analoghi

• 98 | FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) AS INITIAL TREATMENT FOR HIGH TUMOUR BURDEN FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE UK PHASE III PACIFICO TRIAL
  di: A. Pettitt, et al.
  Pubblicazione: (2025)
• 218 | ANALYSIS OF COVID‐19 INFECTIONS WITH FIXED‐DURATION ACALABRUTINIB‐VENETOCLAX COMBINATIONS IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE PHASE 3 AMPLIFY TRIAL
  di: J. R. Brown, et al.
  Pubblicazione: (2025)
• 536 | ORELABRUTINIB‐BASED REGIMENS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL‐WORLD STUDY
  di: Z. Wang
  Pubblicazione: (2025)
• 555 | ADVERSE EVENTS OF INTEREST WITH ZANUBRUTINIB VERSUS FIXED‐DURATION COMBINATION OF VENETOCLAX + OBINUTUZUMAB IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA
  di: N. Lamanna, et al.
  Pubblicazione: (2025)
• 547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
  di: T. Wang, et al.
  Pubblicazione: (2025)